Anteneh M Feyissa1, Gregory A Worrell2, William O Tatum3, Kaisorn L Chaichana4, Mark E Jentoft5, Hugo Guerrero Cazares6, Nileufer Ertekin-Taner7, Steven S Rosenfeld8, Karim ReFaey9, Alfredo Quinones-Hinojosa10. 1. Department of Neurology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL, 32224, United States. Electronic address: Anteneh@mayo.edu. 2. Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, United States; Department of Physiology and Biomedical Engineering, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, United States. Electronic address: Worrell.Gregory@mayo.edu. 3. Department of Neurology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL, 32224, United States. Electronic address: Tatum.william@mayo.edu. 4. Department of Pathology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL, 32224, United States. Electronic address: Chaichana.Kaisorn@mayo.edu. 5. Department of Neurological Surgery, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL, 32224, United States. Electronic address: Jentoft.Mark@mayo.edu. 6. Department of Pathology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL, 32224, United States. Electronic address: Cazares.Hugo@mayo.edu. 7. Department of Neurology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL, 32224, United States. Electronic address: Taner.Nilufer@mayo.edu. 8. Department of Hematology/Oncology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL, 32224, United States. Electronic address: Rosenfeld.Steven@mayo.edu. 9. Department of Pathology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL, 32224, United States. Electronic address: ReFaey.Karim@mayo.edu. 10. Department of Pathology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL, 32224, United States. Electronic address: Quinones-Hinojosa.Alfredo@mayo.edu.
Abstract
PURPOSE: To examine the occurrence of glioma-related preoperative seizures (GPS) and post-operative seizure control (PSC) with respect to patients characteristics including five commonly tested tumor molecular markers (TMMs). METHODS: A single-center retrospective cohort study of patients with glioma evaluated at the Mayo Clinic, Florida between 2016 and 2018. RESULTS: 68 adult patients (mean age = 51-years, 45-males) were included. 46 patients had GPS. 57 patients underwent intra-operative electrocorticography during awake craniotomy-assisted glioma resection. All patients underwent glioma resection (53, gross-total resection) with histologies of pilocytic astrocytoma (n = 2), diffuse astrocytoma (n = 4), oligodendroglioma (n = 14), anaplastic astrocytoma (n = 16), anaplastic oligodendroglioma (n = 1), and glioblastoma (n = 31). 31 (67%) patients had PSC (median follow-up = 14.5 months; IQR = 7-16.5 months). IDH1 mutation (IDH1mut) was present in 32, ARTX retention in 53, MGMT gene promotor methylation in 15, 1p/19q co-deletion in 15, and over-expression of p53 in 19 patients. Patients with IDH1mut were more likely to have GPS (p = 0.037) and PSC (p = 0.035) compared to patients with IDH1 wild-type. Patients with MGMT gene promoter methylation were also likely to have PSC (p = 0.032). GPS or PSC did not differ by age, sex, extent of surgery, glioma grade, location, and histopathological subtype, p53 expression, ARTX retention, or 1p/19q co-deletion status. CONCLUSIONS: GPS and PSC may be associated with IDH1 mutation and MGMT gene promoter methylation status but not other glioma characteristics including tumor grade, location, or histopathology. Prospective studies with larger sample size are needed to clarify the exact mechanisms of GPS and PSC by the various TMMs to identify new treatment targets. Published by Elsevier Ltd.
PURPOSE: To examine the occurrence of glioma-related preoperative seizures (GPS) and post-operative seizure control (PSC) with respect to patients characteristics including five commonly tested tumor molecular markers (TMMs). METHODS: A single-center retrospective cohort study of patients with glioma evaluated at the Mayo Clinic, Florida between 2016 and 2018. RESULTS: 68 adult patients (mean age = 51-years, 45-males) were included. 46 patients had GPS. 57 patients underwent intra-operative electrocorticography during awake craniotomy-assisted glioma resection. All patients underwent glioma resection (53, gross-total resection) with histologies of pilocytic astrocytoma (n = 2), diffuse astrocytoma (n = 4), oligodendroglioma (n = 14), anaplastic astrocytoma (n = 16), anaplastic oligodendroglioma (n = 1), and glioblastoma (n = 31). 31 (67%) patients had PSC (median follow-up = 14.5 months; IQR = 7-16.5 months). IDH1 mutation (IDH1mut) was present in 32, ARTX retention in 53, MGMT gene promotor methylation in 15, 1p/19q co-deletion in 15, and over-expression of p53 in 19 patients. Patients with IDH1mut were more likely to have GPS (p = 0.037) and PSC (p = 0.035) compared to patients with IDH1 wild-type. Patients with MGMT gene promoter methylation were also likely to have PSC (p = 0.032). GPS or PSC did not differ by age, sex, extent of surgery, glioma grade, location, and histopathological subtype, p53 expression, ARTX retention, or 1p/19q co-deletion status. CONCLUSIONS: GPS and PSC may be associated with IDH1 mutation and MGMT gene promoter methylation status but not other glioma characteristics including tumor grade, location, or histopathology. Prospective studies with larger sample size are needed to clarify the exact mechanisms of GPS and PSC by the various TMMs to identify new treatment targets. Published by Elsevier Ltd.
Authors: Ricardo A Domingo; Tito Vivas-Buitrago; Gaetano De Biase; Erik H Middlebrooks; Perry S Bechtle; David S Sabsevitz; Alfredo Quiñones-Hinojosa; William O Tatum Journal: Oper Neurosurg (Hagerstown) Date: 2021-07-15 Impact factor: 2.703
Authors: Yahya Ahmadipour; Laurèl Rauschenbach; Alejandro Santos; Marvin Darkwah Oppong; Lazaros Lazaridis; Carlos M Quesada; Andreas Junker; Daniela Pierscianek; Philipp Dammann; Karsten H Wrede; Björn Scheffler; Martin Glas; Martin Stuschke; Ulrich Sure; Ramazan Jabbarli Journal: Neurooncol Adv Date: 2020-11-18
Authors: Marco Zoccarato; Lucia Nardetto; Anna Maria Basile; Bruno Giometto; Vittorina Zagonel; Giuseppe Lombardi Journal: Front Oncol Date: 2021-03-22 Impact factor: 6.244